Analytical Data
-
基因名
HLA-A*01:01&B2M&MAGE-A3(EVDPIGHLY) Monomer
- Application
-
别名
MAGE family member A3; HIP8; HYPD; CT1.3; MAGE3; MAGEA6
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5SUL5 (G25-T305)&P61769
-
表达区间
Q5SUL5 (G25-T305)&P61769 (I21-M119)&EVDPIGHLY
-
分子量
53-63 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*01:01/B2M/MAGE-A3(EVDPIGHLY) tetramer recombinant protein is rooted in the exploration of immune responses against cancer. MAGE-A3 is a tumor-associated antigen frequently expressed in various malignancies, making it a compelling target for immunotherapy. The HLA-A*01:01 molecule, a specific variant of the major histocompatibility complex (MHC) class I, presents peptide fragments to T cells, enabling the immune system to recognize and eliminate tumor cells. By creating a tetrameric complex of HLA-A*01:01 and the MAGE-A3-derived peptide EVDPIGHLY in conjunction with beta-2-microglobulin (B2M), researchers aim to effectively visualize and characterize T cells that specifically recognize cancer cells expressing this antigen. This tetrameric approach allows for the identification and quantification of antigen-specific T cells in blood samples from cancer patients, thus providing insights into the immune landscape of tumors. Such investigations are significant for the development of personalized cancer vaccines and adoptive T cell therapies, aiding in the design of treatments that enhance the body’s immune response against cancerous cells while sparing normal tissues. Understanding the dynamics of these specific T cell responses can inform both prognostic assessments and therapeutic strategies, ultimately leading to improved clinical outcomes in oncology.
